NYSE$BHVN
Biohaven Ltd old · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Biohaven reported Q2 2025, net loss of $198.1M, diluted EPS of $-1.15.
For Q2 2025, Biohaven reported a net loss of $198.1M, diluted EPS was $-1.15. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Net loss $198.1M.
- Diluted EPS $-1.15.
- Biohaven MD&A highlights liquidity, capital, and core trends.
- Segment and macro factors shape year-over-year comparisons.
Headline financials
Revenue & EPS history
Biohaven · Revenue · Quarterly
$0
Forward guidance
Clinical-stage and growth biotech discuss trial milestones, cash runway, and partnership optionality.
Tailwinds
- Pipeline progress and data readouts.
- Cash runway from recent financings.
- Licensing or collaboration potential.
Headwinds
- Trial failure or regulatory delays.
- Dilution from equity raises.
- Commercialization timing uncertainty.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q2 2025
-0.5%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+7.7%
Avg return
30 days after
50%
7 / 14 earnings
Positive
+12.6%
Q2 2024
Best reaction
-12.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -9.7% | -16.0% | -17.0% | |
| Q3 2024 | -6.5% | +0.5% | +28.3% | |
| Q3 2025 | -5.7% | +0.5% | +28.3% | |
| Q2 2025 | -9.0% | +6.6% | -5.0% | |
| Q1 2025 | +0.0% | -3.7% | -5.2% | |
| Q4 2024 | -2.2% | -7.1% | -36.3% | |
| Q2 2024 | +12.6% | +13.7% | +6.7% | |
| Q1 2024 | -12.5% | -8.7% | -17.5% | |
| Q4 2023 | +4.7% | +24.0% | +15.6% | |
| Q3 2023 | +1.0% | +4.6% | +30.9% | |
| Q2 2023 | +3.1% | +3.4% | -3.3% | |
| Q1 2023 | +5.3% | +2.2% | +72.6% | |
| Q4 2022 | +10.4% | +5.4% | +10.8% | |
| Q3 2022 | +1.2% | +2.2% | -0.9% | |
| Q2 2022 | — | — | — | |
| Q1 2022 | — | — | — | |
| Q4 2021 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro